|
EP0876345B1
(en)
*
|
1995-10-16 |
2004-08-18 |
Fujisawa Pharmaceutical Co., Ltd. |
Heterocyclic compounds as h+-atpases
|
|
GB9712761D0
(en)
*
|
1997-06-17 |
1997-08-20 |
Chiroscience Ltd |
Quinolines and their therapeutic use
|
|
GB9824160D0
(en)
*
|
1998-11-04 |
1998-12-30 |
Darwin Discovery Ltd |
Heterocyclic compounds and their therapeutic use
|
|
US6262070B1
(en)
|
1998-11-04 |
2001-07-17 |
Darwin Discovery Ltd. |
Heterocyclic compounds and their therapeutic use
|
|
EP1671651B1
(en)
*
|
1999-08-21 |
2009-11-11 |
Nycomed GmbH |
Synergistic combination of pumafentrine and salmeterol
|
|
WO2001032658A1
(en)
*
|
1999-11-02 |
2001-05-10 |
Ajinomoto Co., Inc. |
Polyazanaphthalene compound and medicinal use thereof
|
|
JP4603646B2
(ja)
*
|
1999-11-15 |
2010-12-22 |
富士フイルムファインケミカルズ株式会社 |
新規なジピリジル誘導体
|
|
US7217722B2
(en)
|
2000-02-01 |
2007-05-15 |
Kirin Beer Kabushiki Kaisha |
Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
|
|
GB0003256D0
(en)
*
|
2000-02-11 |
2000-04-05 |
Darwin Discovery Ltd |
Heterocyclic compounds and their therapeutic use
|
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
|
DE10035928A1
(de)
|
2000-07-21 |
2002-03-07 |
Asta Medica Ag |
Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
|
|
US7112594B2
(en)
|
2000-08-09 |
2006-09-26 |
Mitsubishi Pharma Corporation |
Fused bicyclic amide compounds and medicinal use thereof
|
|
US6953774B2
(en)
|
2000-08-11 |
2005-10-11 |
Applied Research Systems Ars Holding N.V. |
Methods of inducing ovulation
|
|
JP2002300373A
(ja)
*
|
2001-03-30 |
2002-10-11 |
Minolta Co Ltd |
画像処理方法、画像処理装置、記録媒体及びプログラム
|
|
EP1389467B1
(en)
|
2001-05-23 |
2013-07-03 |
Mitsubishi Tanabe Pharma Corporation |
Therapeutic composition for the regenerative treatment of cartilage diseases
|
|
CN1520313A
(zh)
*
|
2001-05-23 |
2004-08-11 |
������ҩ��ʽ���� |
一种加速骨折愈合的组合物
|
|
ATE341545T1
(de)
|
2001-07-16 |
2006-10-15 |
Astrazeneca Ab |
Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
|
|
CN100506817C
(zh)
*
|
2001-08-15 |
2009-07-01 |
纳幕尔杜邦公司 |
用于防治无脊椎害虫的邻-杂环取代的芳基酰胺类化合物
|
|
KR20040075004A
(ko)
|
2001-12-14 |
2004-08-26 |
어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. |
비폴리펩티드 고리에이엠피 레벨 모듈레이터를 이용한배란 유도 방법
|
|
MY140561A
(en)
|
2002-02-20 |
2009-12-31 |
Nycomed Gmbh |
Dosage form containing pde 4 inhibitor as active ingredient
|
|
SE0200920D0
(sv)
*
|
2002-03-25 |
2002-03-25 |
Astrazeneca Ab |
Novel compounds
|
|
ES2195785B1
(es)
*
|
2002-05-16 |
2005-03-16 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de piridazin-3(2h)-ona.
|
|
AU2002950217A0
(en)
|
2002-07-16 |
2002-09-12 |
Prana Biotechnology Limited |
8- Hydroxy Quinoline Derivatives
|
|
ES2211344B1
(es)
*
|
2002-12-26 |
2005-10-01 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de piridazin-3(2h)-ona.
|
|
TWI324150B
(en)
*
|
2003-02-28 |
2010-05-01 |
Novartis Ag |
Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
|
|
AU2004226353A1
(en)
|
2003-04-01 |
2004-10-14 |
Laboratoires Serono Sa |
Inhibitors of phosphodiesterases in infertility
|
|
PE20050211A1
(es)
*
|
2003-04-02 |
2005-04-27 |
Novartis Ag |
Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
|
|
US20070281931A1
(en)
*
|
2003-05-29 |
2007-12-06 |
Nigel Boughton-Smith |
Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
|
|
JP2007501270A
(ja)
*
|
2003-05-29 |
2007-01-25 |
アストラゼネカ・アクチエボラーグ |
Ｐ２Ｘ７受容体アンタゴニストおよび腫瘍壊死因子αを含む医薬組成物
|
|
US20070010497A1
(en)
*
|
2003-05-29 |
2007-01-11 |
Nigel Boughton-Smith |
Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
|
|
GB0312609D0
(en)
*
|
2003-06-02 |
2003-07-09 |
Astrazeneca Ab |
Novel compounds
|
|
SE0302139D0
(sv)
*
|
2003-07-28 |
2003-07-28 |
Astrazeneca Ab |
Novel compounds
|
|
SE0302192D0
(sv)
*
|
2003-08-08 |
2003-08-08 |
Astrazeneca Ab |
Novel compounds
|
|
ES2286685T3
(es)
*
|
2003-09-15 |
2007-12-01 |
Schering Corporation |
Sintesis de quinolein 5-carboxamidas utles para la preparacion de inhibidores de pde iv.
|
|
SE0302488D0
(sv)
*
|
2003-09-18 |
2003-09-18 |
Astrazeneca Ab |
New combination
|
|
BRPI0417543A
(pt)
|
2003-12-12 |
2007-03-27 |
Wyeth Corp |
quinolinas úteis no tratamento de doença cardiovascular
|
|
DK2666481T3
(en)
*
|
2003-12-26 |
2019-02-25 |
Masatoshi Hagiwara |
A method for regulating the phosphorylation of SR protein and antiviral agents comprising an SR protein activity regulator as the active ingredient
|
|
EA010369B1
(ru)
*
|
2004-02-04 |
2008-08-29 |
Пфайзер Продактс Инк. |
Замещенные хинолиновые соединения
|
|
BRPI0509583A
(pt)
*
|
2004-04-01 |
2007-10-09 |
Hoffmann La Roche |
composições farmacêuticas de pirimidina-2,4,6-trionas
|
|
RU2417993C9
(ru)
*
|
2004-05-18 |
2011-10-10 |
Шеринг Корпорейшн |
Замещенные 2-хинолилоксазолы, пригодные в качестве ингибиторов фдэ4
|
|
ES2251866B1
(es)
*
|
2004-06-18 |
2007-06-16 |
Laboratorios Almirall S.A. |
Nuevos derivados de piridazin-3(2h)-ona.
|
|
ES2251867B1
(es)
*
|
2004-06-21 |
2007-06-16 |
Laboratorios Almirall S.A. |
Nuevos derivados de piridazin-3(2h)-ona.
|
|
GB0413960D0
(en)
*
|
2004-06-22 |
2004-07-28 |
Novartis Ag |
Organic compounds
|
|
ME02799B
(me)
|
2004-06-24 |
2018-01-20 |
Vertex Pharma |
Modulatori ATP-vezujućih kasetnih transportera
|
|
US8354427B2
(en)
*
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
|
SA05260265A
(ar)
*
|
2004-08-30 |
2005-12-03 |
استرازينيكا ايه بي |
مركبات جديدة
|
|
AU2005293196B2
(en)
*
|
2004-10-12 |
2012-03-22 |
Actelion Pharmaceuticals Ltd |
1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt
|
|
CN101044135B
(zh)
*
|
2004-10-19 |
2011-11-23 |
霍夫曼-拉罗奇有限公司 |
喹啉衍生物
|
|
SE0402925D0
(sv)
*
|
2004-11-30 |
2004-11-30 |
Astrazeneca Ab |
Novel Compounds
|
|
US8686002B2
(en)
|
2005-08-21 |
2014-04-01 |
AbbVie Deutschland GmbH & Co. KG |
Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
|
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
EP2275096A3
(en)
|
2005-08-26 |
2011-07-13 |
Braincells, Inc. |
Neurogenesis via modulation of the muscarinic receptors
|
|
AU2006304787A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
|
CA2625210A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
EP1979367A2
(en)
*
|
2005-12-24 |
2008-10-15 |
Vertex Pharmaceuticals Incorporated |
Quinolin-4-one derivatives as modulators of abc transporters
|
|
CA2635581C
(en)
|
2005-12-28 |
2017-02-28 |
Vertex Pharmaceuticals Incorporated |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
KR100821649B1
(ko)
*
|
2006-01-24 |
2008-04-11 |
서울시립대학교 산학협력단 |
클리오퀴놀을 유효성분으로 포함하는 ＨＩＦ-1α 활성제
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
AU2007249399A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
SG173366A1
(en)
*
|
2006-07-11 |
2011-08-29 |
Schering Corp |
Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
|
|
JPWO2008026687A1
(ja)
|
2006-09-01 |
2010-01-21 |
杏林製薬株式会社 |
ピラゾロピリジンカルボキサミド誘導体及びそれらを含有するホスホジエステラーゼ（ｐｄｅ）阻害剤
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
CL2007003874A1
(es)
*
|
2007-01-03 |
2008-05-16 |
Boehringer Ingelheim Int |
Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
|
|
ES2306595B1
(es)
*
|
2007-02-09 |
2009-09-11 |
Laboratorios Almirall S.A. |
Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
|
|
ES2320954B1
(es)
*
|
2007-03-02 |
2010-03-16 |
Laboratorio Almirall S.A. |
Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona.
|
|
AU2008228067B2
(en)
*
|
2007-03-22 |
2011-12-08 |
Astrazeneca Ab |
Quinoline derivatives for the treatment of inflammatory diseases
|
|
US9321730B2
(en)
|
2007-08-21 |
2016-04-26 |
The Hong Kong Polytechnic University |
Method of making and administering quinoline derivatives as anti-cancer agents
|
|
US8106073B2
(en)
|
2007-11-30 |
2012-01-31 |
Astrazeneca Ab |
Quinoline derivatives 057
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
SI2408750T1
(sl)
|
2009-03-20 |
2015-11-30 |
Vertex Pharmaceuticals Incorporated |
Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
|
|
JP2011042643A
(ja)
*
|
2009-07-24 |
2011-03-03 |
Bayer Cropscience Ag |
殺虫性カルボキサミド類
|
|
EP2569285A1
(en)
|
2010-05-10 |
2013-03-20 |
Gilead Sciences, Inc. |
Bifunctional quinoline derivatives
|
|
WO2011143106A1
(en)
|
2010-05-10 |
2011-11-17 |
Gilead Sciences, Inc. |
Bi - functional pyrazolopyridine compounds
|
|
WO2013074059A2
(en)
*
|
2010-11-05 |
2013-05-23 |
Regents Of The University Of Minnesota |
Cytosine deaminase modulators for enhancement of dna transfection
|
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
CN102603628B
(zh)
|
2010-12-22 |
2016-08-17 |
香港理工大学 |
作为抗癌试剂的喹啉衍生物
|
|
WO2013106547A1
(en)
|
2012-01-10 |
2013-07-18 |
President And Fellows Of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
|
HK1203840A1
(en)
|
2012-02-27 |
2015-11-06 |
沃泰克斯药物股份有限公司 |
Pharmaceutical composition and administration thereof
|
|
CN103285373A
(zh)
*
|
2013-05-30 |
2013-09-11 |
苏州普罗达生物科技有限公司 |
肿瘤坏死因子-α多肽抑制剂制备及其应用
|
|
CN103254291B
(zh)
*
|
2013-05-30 |
2014-06-25 |
常州亚当生物技术有限公司 |
肿瘤坏死因子-α多肽抑制剂及其应用
|
|
EP3626717A1
(en)
*
|
2013-10-14 |
2020-03-25 |
Eisai R&D Management Co., Ltd. |
Selectively substituted quinoline compounds
|
|
JP6746569B2
(ja)
|
2014-10-07 |
2020-08-26 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶
|
|
RU2624906C2
(ru)
*
|
2015-12-22 |
2017-07-10 |
федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации |
Производные 2-хинальдинкарбоновой кислоты и их противогриппозная активность
|
|
BR112020004982A2
(pt)
|
2017-09-13 |
2020-09-15 |
Syngenta Participations Ag |
derivados microbiocidas de (tio)carboxamida de quinolina
|
|
CN107812006A
(zh)
*
|
2017-11-13 |
2018-03-20 |
全椒先奇医药科技有限公司 |
一种治疗急性肾衰药物组合物及其应用
|